Executive Salary
avg.$223,000
LivaNova
Life Science/Medical Technology
Bexley, United Kingdom
Description
LivaNova, founded in 2015 and publicly traded, is a medical device manufacturer specializing in cardiac surgery and neuromodulation. The company employs approximately 2,900 people and generated a total revenue of $1.3 billion. Its operations are primarily B2B, serving healthcare providers with innovative medical devices for cardiac and neurological applications. While headquartered in London, England, LivaNova maintains a significant presence in the United States, supporting its extensive portfolio and customer base. The company’s offerings are designed to improve patient outcomes through advanced medical technologies in the cardiovascular and neuromodulation fields.
Experteer Insights
Experteer Briefing
Company Trajectory
LivaNova, headquartered in London, England, United Kingdom, has established itself within the medical device manufacturing industry with a specialized focus on solutions for cardiac surgery and neuromodulation. Since its founding in 2015, the company has maintained a business model centered on developing advanced medical devices for highly specialized clinical applications. Key milestones in its history include a commitment to innovation and the expansion of its product lineup, supporting strategic market growth within and beyond its core areas. Notably, LivaNova operates as a mature, established enterprise rather than a start-up, signaling its sustained progression through targeted market development and refinement of its offerings.
Financial Setup
LivaNova operates as a publicly traded entity, serving a primarily business-to-business (B2B) clientele with advanced medical technology. The company employs approximately 2,900 people worldwide, reflecting a significant operational footprint to support its global reach. Its financial strategy has evolved alongside market and technological developments, with a consistent emphasis on developing and delivering specialized devices for cardiac surgery and neuromodulation. Revenue generation is deeply connected to its portfolio of medical devices designed for high-impact clinical use, reflecting resilience and adaptability in the face of industry changes.
Development & Outlook
Recent and ongoing developments at LivaNova include the continued introduction and enhancement of medical devices such as vagus nerve stimulation therapy systems, heart-lung machines, oxygenators, and perfusion tubing systems. The company places notable emphasis on research and development programs, particularly through patents related to vagus nerve stimulation and cardiopulmonary support devices. LivaNova maintains compliance with ISO standards and relevant medical device regulations, underscoring its commitment to quality and regulatory excellence. Looking forward, the company aims to strengthen its market position through sustained innovation, expansion of its therapeutic solutions, and continued adherence to global best practices in medical technology.